“Global tissue diagnostics market is expected to reach $8.24 Bn by 2029”, says Visiongain

08 January 2020
Pharma

Visiongain’s new report the Tissue Diagnostics Market Report : Forecasts by Product (Consumables, Instruments), by Product (Immunohistochemistry, in Situ Hybridization, Digital Pathology, Others), by Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer, Others), by End User (Hospitals, Research Labs, Pharmaceutical Companies, Research Organizations), plus analysis of leading companies operating in the global tissue diagnostics market.

In 2019, the global tissue diagnostics market was valued at $4.09 billion and is expected to reach $8.24 billion by 2029 at a CAGR of 7.2% over the forecast period. Rising cancer prevalence all over the world, expanding healthcare infrastructure in developing countries, growing healthcare diagnostics affordability, technological advancement in imaging, and growth in personalized therapeutics is expected to increase tissue diagnostics market expansion over the projected period.

Improving healthcare infrastructure in developing countries such as India, China, Indonesia, Singapore, Malaysia, South Korea, Brazil, and Colombia is expected to encourage healthcare service providers to expand their facilities in these countries. Additionally, increasing disposable income followed by increasing healthcare spending has increased market penetration of tissue diagnostics over the past few years and the trend is expected to continue over the course of time.

Technological advancement in tissue diagnostics is expected to open avenues in the global healthcare industry. For instance, in 2018, According to University of Illinois, a new microscope system can image living tissue in real time and in molecular detail, without any chemicals or dyes. Some other prominent technologies innovated in 2017 are a Mass Spec Pen To Rapidly Identify Cancer, Paper Point-of-Care Zika Test, Transparent Tissues for Pathological Diagnosis, Paper-based Electrochemical Diagnostics, Microfluidic Chip to Predict Preterm Birth, Smartphone TRI Analyzer, and Wearable Sweat Sensor.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021

Read

Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021

Read

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever